Development of a Rapid Automated Point-of-Care Test for *Mycobacterium tuberculosis*

Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System

Matthew A. Butzler[1,2†], Jennifer L. Reed[1,2†], Alaina M. Olson[3], Rachel C. Wood[3], Gerard A.

Cangelosi[3], Angelique K. Luabeya[4], Mark Hatherill[4], Arthur M. Chiwaya[5], Loren Rockman[5],

Grant Theron[5], and Sally M. McFall[1,2*]

[1]Center for Innovation in Global Health Technologies, Robert J. Havey Institute for Global

Health, Northwestern University Feinberg School of Medicine, Chicago, Illinois, 60611, USA

[2]Department of Biomedical Engineering, Northwestern University, Evanston, IL 60208, USA

[3]Department of Environmental and Occupational Health Sciences, University of Washington,

Seattle, Washington, USA

[4]South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease & Molecular

Medicine and Department of Pathology, University of Cape Town, Cape Town, South Africa

[5]DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, South African Medical

Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human

Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa

[†]These authors contributed equally to this work.

[*]Author to whom all correspondence should be sent.

Sally McFall, PhD

Email: s-mcfall@northwestern.edu

Phone: 847-467-2560

Fax: 847-491-4928

Abstract

Mycobacterium tuberculosis (MTB) disease is a major global health threat with most

tuberculosis (TB) cases occurring in low-and middle-income countries (LMIC) with limited

healthcare infrastructure. Near-point-of-care testing which can be deployed at peripheral clinical

settings is needed to start treatment earlier and thereby improve treatment outcomes. Here we

report the development and preliminary characterization of an MTB detection assay that utilizes

tongue swab or sputum specimens for The DASH® Rapid PCR System which employs

cartridge-based automated sequence specific capture sample prep combined with dual target

qPCR multicopy MTB insertion sequences IS*6110* and IS*1081* amplification and detection. MTB

is resistant to conventional bacterial lysis techniques; therefore, we evaluated two pre-cartridge

lysing techniques, mechanical lysis and sonication, and selected sonication for all subsequent

studies. The DASH MTB assay demonstrated a limit of detection of 2.5 MTB cells/swab with no

detection of 10 non-tuberculosis *Mycobacterium* strains. Clinical testing of 100 (49 positive and

51 negative) de-identified blinded sputa from South African symptomatic clinic attendees yielded

an overall test sensitivity of 96% (100% for smear positive samples and 88% for smear negative

samples) and specificity of 88% when compared to sputum culture. In a separate study of 110

tongue swab specimens (70 positive and 40 negative) from South African symptomatic clinic

attendees, the sensitivity was 93% and the specificity was 100%. We further demonstrated that

the test is compatible with peripheral LMIC settings via external battery operation and cartridge

stability at 45°C for up to one year.

Importance

Tuberculosis (TB) is the single most deadly infectious disease with 1.23 million deaths in 2024.

Near-point-of-care testing which can be deployed at peripheral settings that lack laboratory

infrastructure to deliver prompt and accurate diagnosis is needed to start treatment earlier and

thereby improve treatment outcomes. In this study, we have developed an automated test to

detect *Mycobacterium tuberculosis* (MTB), the cause of TB, from sputum and tongue swab

specimens. Its high sensitivity and specificity, rapid time to result, and compatibility with

environments that lack air conditioning and consistent electricity make this assay suitable for

diverse clinical settings.

Introduction

Tuberculosis (TB) is the leading cause of death from a single infectious disease with more than

10 million people contracting TB resulting in 1.23 million deaths in 2024 with most deaths

occurring in low-and-middle income countries (1, 2). Delayed and missed diagnosis is a major

impediment in providing TB care (3) . Centralized testing can lead to extensive delays in results

and loss to follow up in the care cascade. Near-point-of-care (nPOC) testing using instruments

that are preferably battery operated and do not require specialized training or laboratory

infrastructure would enable diagnosis and treatment decisions to be made in the first patient

encounter with potential for improved treatment outcomes (2).

Sputum is the primary specimen type for detecting pulmonary TB because it has a higher

bacillary load than non-sputum specimens (4). However, up to one third of people being tested

for pulmonary TB cannot expectorate sputum leading to a high burden of undiagnosed TB (5).

In addition, sputum collection including sputum induction, if necessary, can be logistically

challenging in some settings including infection control risks. In response to these limitations,

alternative sample types such as tongue swabs are being evaluated. Tongue swab collection is

non-invasive, readily adapted for self-collection, and has a very high sample collection yield

ensuring that a sample is available even when sputum cannot be expectorated (6). The

specificity of tongue swab specimens with molecular readouts, relative to sputum testing is

consistently high. Sensitivity, however, is variable depending on population and methodology (7-

13). Tongue swab specimen testing can be very sensitive among people with high bacillary

loads, but less when applied to people with lower bacillary loads. Nonetheless, in patient

populations and settings where sputum collection is not practical, tongue swab testing may offer

a useful alternative (14).

The DASH® Rapid PCR System (Figure 1a) is a sample-to-answer platform that performs rapid,

simple, durable, and low-cost infectious disease testing for multiple sample types such as

respiratory swabs, whole blood, and plasma (15-17). We have adapted a previously published

manual assay to detect *Mycobacterium tuberculosis* (MTB) that processes sputum via sequence

specific capture to reduce amplification interferents that matched the sensitivity of culture (18,

19) for inclusion in the DASH test cartridge (Figure 1B). Since MTB is resistant to conventional

bacterial lysis techniques, we also evaluated mechanical lysis and sonication as two pre-

cartridge sample treatments for improved lysis.

The objectives of this study were to optimize MTB assay performance on the DASH platform,

determine the feasibility of testing tongue swabs or sputa as specimens by evaluating the test's

analytical and clinical performance, and demonstrate that the DASH analyzer is compatible with

peripheral LMIC settings via external battery operation and cartridge stability at elevated

temperatures.

Materials and Methods

Strains

MTB H37Ra was acquired from the American Type Culture Collection (ATCC; Manassas, VA)

and used as a positive control for assay development. Table 1 contains strains used in the

specificity studies. The concentration of *Mycobacterium tuberculosis* H37Ra cells from ATCC

was estimated by comparing to quantified *Mycobacterium tuberculosis* H37Ra cells sourced

from the University of Washington which were cultured and quantified by optical density as

previously described (20). DNA from both cell sources was purified using Dynabeads® SILANE

genomic DNA Kit (Thermo Fisher, Waltham, MA, USA) following manufacturer's instructions. A

standard curve was prepared by making tenfold dilutions ranging from 100,000 genomic copies

to 10 genomic copies of the reference DNA. Ten-, 100-, and 1000-fold dilutions of the unknown

DNA were prepared, and samples were evaluated using an assay targeting the IS*1081* insertion

element (IS1081 F4, 5'- TGAACGCGCACTGACCA-3', IS1081 R4, 5'-

CTTTGGCCATGATCGACACTT-3', IS1081 P2, 5'-

TEX615/CTGCTACCTGCTGGGAGTATCCACT-3').

Swab control specimens

Swab used for contriving specimens were collected from healthy volunteers using Copan

FLOQSwab (520CS01; Copan Italia, Brescia, IT) and stored at -80 °C until use.

Swab clinical samples

Twenty-three pairs of swabs from TB positive donors provided by Rapid Research in

Diagnostics Development for TB Network were used to compare lysis methods (Supplemental

Methods; Table S1). The swab pairs were either Copan FLOQSwab (520CS01) or Steripack

swab (60564RevC) stored dry at -80°C. Specimen data provided included sputum

microbiological reference standard (MRS) results, sputum GeneXpert Ultra MTB/RIF (Xpert

Ultra) semiquantitative results, and sputum culture results if the Xpert Ultra baseline result was

negative. Five of the positive specimen pairs were High, 7 were Medium, 4 were Low, 5 were

Very Low, 0 were Trace, and 2 were Xpert Ultra negative and culture positive.

Ten positive and 20 negative tongue swab specimens were provided by the Theron lab. Tongue

swabs were collected using the Copan FLOQSwab (520CS01) from a cohort of adults self-

reporting with presumptive pulmonary TB symptoms meeting WHO criteria (at least one

symptom for people living with (PLHIV), ≥2 for those without HIV) and recruited at clinics in

Cape Town, South Africa. The standard WHO-defined symptoms for TB were used (cough,

weight loss, fever, drenching night sweats); with two required if living without HIV and one for

PLHIV (for those without HIV, a cough needed to have persisted for at least two weeks; for

PLHIV, any cough duration qualified). Tongue swabs were collected dry and stored at -80 °C

following collection and until processed.

One hundred ten swab specimens (Copan FLOQSwab 520CS01) were previously collected

from a cohort of South African participants by the South African Tuberculosis Vaccine Initiative

as previously described (10, 13, 20). Participants with presumptive TB were enrolled in a clinical

setting in Worcester South Africa between July 2021 and March 2023. Swabs not used in earlier

studies were identified for testing in the present study and were shipped to Northwestern for

processing from Seattle, Washington. All available swabs from participants with

microbiologically confirmed pulmonary TB and available sputum Xpert Ultra semiquantitative

data (N = 70) were selected for testing. An additional set (N = 40) of confirmed TB-negative

participants was selected randomly for specificity calculations (STARD diagram). Samples were

tested in a blinded fashion. Duplicate swab specimens from the same participants were tested

in blinded fashion by using Xpert Ultra, as part of a previous study as described by Wood et al

(13). All swabs were collected before sputum collection, or ≥1 hour after sputum collection.

Sputum control specimens

Residual deidentified TB negative sputum specimens were provided by the microbiology

department of the Mayo Clinic or were purchased from Tricore Reference Laboratories

(Albuquerque, NM). Pooled sputum was prepared by vortexing twelve MTB-negative donor

specimens totaling approximately 15 mL in a 50 mL conical tube with ~5 grams of 5 mm acid-

washed glass beads until homogenous.

Sputum clinical specimens

One hundred sputum specimens were provided by Theron lab from a cohort described

previously (21, 22). 51 were negative and 49 positive by sputum culture. Adults presenting with

presumptive TB provided three sputum samples (each ≥1 mL, nonsalivary) over two

consecutive workdays. The first sample underwent culture and smear microscopy, the second

was tested with Xpert Ultra, and the third used for the DASH assay. GenoType MTBDRplus

(v2.0; Bruker-Hain Life Sciences, Nehren, Germany) was performed on culture-positive isolates

for MTBC and rifampicin resistance detection. (Figure 2).

Sampling of sputum swabs

The volume of sputum retained on a swab was estimated as follows. Five swabs were dipped

into aliquots of prepared pooled sputum and swirled 2-3 times, then were broken off into pre-

massed 2.0 mL conical tubes. Three clean, broken-off swab heads were weighed and the

average mass of the swab head plus tube were subtracted from the measured mass to

calculate the mass of the sputum retained on the swab. This process was repeated with fifteen

individual sputum specimens.

DASH PCR System

The DASH platform achieved 510(k) FDA clearance in CLIA-waived settings for the DASH

SARS-CoV-2 & Flu A/B multiplexed test and the DASH platform in 2024. Like central laboratory

instruments, the DASH system extracts and concentrates target nucleic acid followed by qPCR

amplification and detection. The fully integrated DASH cartridge (Figure 1B) consists of six

sample-preparation chambers in the cartridge body, a liquid transfer capsule (LTC) which is

used to transfer liquids between chambers, and a PCR chamber in the microfluidic extension.

The analyzer extracts the target nucleic acid and binds targets of interest to paramagnetic

particles (PMPs) via sequence-specific capture. The PMPs carrying the targets are separated

magnetically from the lysis buffer, washed, and transported into the PCR chamber. The purified

nucleic acid is eluted from the PMPs then amplified and detected by qPCR.

Sonication Prototype

The sonicator consists of a circuit board (Sonics & Materials, Inc. Part No. KITVC544)

connected to a probe (Sonics & Materials, Inc. Part No. CV301) and is powered by an AC-DC

power supply (CUI, Inc. Model 3A-621DN24) outputting 24V at 2.5A. The sonication

power/amplitude was modulated using a potentiometer (Honeywell Part No. 309NPC10K) wired

into the board. To set the amplitude to reproducible values, a gauge was printed and adhered

around the potentiometer such that the arc traced by turning the potentiometer begins at "0" and

ends at "10". The sonicator probe interfaces with the sample tube (USA Scientific 2 mL

polypropylene screwcap tubes, #1420-9710; Ocala, FL, USA) by way of a custom 3D printed

fixture that centers the bottom of the tube onto the probe.

Research Use Only (RUO) DASH MTB Assay

The RUO DASH MTB Test is an automated qPCR assay intended for the qualitative detection

of DNA from *Mycobacterium tuberculosis* complex organisms in tongue swab or sputum

specimens. The test cartridge contains all the reagents required for the analyzer to

automatically process a pre-lysed clinical sample and run the MTB test. Cartridge-specific

reagents and cartridges were manufactured in the Northwestern University pilot manufacturing

facility. Using DASH script software, the times, and temperatures of the sequence-specific

hybridization, biotin-streptavidin binding, and the qPCR extension and denaturation steps were

optimized.

The DASH MTB assay targets two multicopy regions of the MTB genome, IS*6110* and

IS*1081,* which are detected in the same fluorescent channel. In lieu of primer sequences, the

clarified Minimum Information for Publication of Quantitative Real-Time PCR Experiments

(MIQE) guidelines allow publication of the reference sequence, anchor nucleotide (defined as a

nucleotide located in the probe sequence), and amplicon length for each assay (23, 24). The

IS*6110* amplicon context is NC_000962, 889,840, 100. The IS*1081* amplicon context is

NC_000962, 1,169,640, 97. A synthetic DNA procedural control (PRC) is included to control

for sample purification, nucleic acid amplification, and to monitor for the presence of inhibitors

in the qPCR test. The synthetic DNA molecule contains a control amplicon and sequence-

specific capture probe sequences used for capturing the IS*1081* DNA targets. The procedural

control is fluorescently detected in a second channel on the DASH analyzer. At the completion

of the test, the fluorescence readings from the MTB and the procedural control are processed

by calculating the quantification cycle (Cq) of each channel and interpreting the result as either:

MTB positive, MTB negative, invalid, or error.

Test Workflow

The user collected either a tongue swab specimen or a sputum specimen on a swab (Figure

1C), inserted the swab into a flat-bottom 2 mL tube containing 600 µL of lysis buffer and 150-

200 mg 0.1 mm diameter glass beads (Benchmark Scientific, Edison, NJ, USA). Samples were

sonicated for 3 minutes at a power/amplitude of "4" with a downward force of 25-30N using a

force gauge (SHIMPO; Model FG-3006; ELECTROMATIC Equipment Co.,

Lynbrook, NY, USA). Approximately 450 µL of specimen was transferred with a pipet to the

DASH cartridge, the cartridge cap is closed, and the cartridge is inserted into the DASH

analyzer. After 14.5 minutes, an easy-to-read positive/negative result appears on the unit's

touch screen.

Limit of Detection

Mycobacterium tuberculosis H37Ra cells were diluted to 1e0 cells/µL and twofold serial dilutions

were prepared three times in 10 mM Tris pH=8 (Invitrogen, Waltham, MA, USA), 15 % glycerol

v/v (Acros Organics, now Thermo Fisher, Waltham, MA, USA), 0.05 % Tween-80 (Thermo

Fisher). Twenty microliters of diluted MTB were added to a freshly thawed tongue swab, and the

swab was processed using the sample workflow described above. Because 5/5 replicates were

detected at 10 cells/swab, twenty replicates were collected at 2.5 cells/swab.

Specificity

DNA from fourteen nontuberculous mycobacteria (NTM) or other pathogenic organisms that

may be present in tongue swabs were tested for cross-reactivity and assay interference (Table

1). For the cross-reactivity evaluation, DNA or cells of each organism were added to a cartridge

at the desired concentration with a tongue swab from an MTB-negative volunteer, in triplicate.

For the interference evaluation, the cartridges were prepared as for cross-reactivity but with the

addition of 60 MTB cells (3X LoD) per tongue swab.

Purified genomic DNA was used for all potentially interfering microbial organisms except for

Streptococcus salivarius, where frozen bacteria were used. The concentrations of all nucleic

acid additions were determined spectrophotometrically except for *S. salivarius* which was

determined using a standard curve (supplemental methods).

Clinical Evaluation of swabs

Tongue swabs were removed from -80 °C storage and placed directly into sonication tubes

containing 600 µL lysis buffer and glass beads. Samples were left for a minimum of 5 minutes to

equilibrate to room temperature before performing the test workflow.

Amplification Efficiency with Sputum Specimens

Mycobacterium tuberculosis H37Ra cells were diluted to 2e5 cells/µL and five tenfold serial

dilutions were prepared in 10 mM Tris pH=8 (Invitrogen), 15 % glycerol v/v (Acros), 0.05 %

Tween-80 (Thermo). Each sample consisted of 10 µL of diluted MTB added to 100 µL negative

pooled sputum, and each concentration was evaluated in replicates of 4. The entire prepared

sample was collected on a flocked swab (Copan) and processed using the standard workflow.

Clinical Evaluation of sputum specimens

49 culture positive and 51 culture negative sputum specimens were sampled by firmly pressing

a Copan FLOQSwab into each sample tube while rotating the swab to load as much sputum as

possible onto the swab head. The swab head was broken off into a flat-bottom sonication tube

and processed via the test workflow.

Cross-Contamination Studies

To confirm the absence of cross-contamination between assay runs, alternating runs of high

positive and negative samples were run. The high positive sputum samples contained 14.3

million *Mycobacterium tuberculosis* H37Ra cells spiked into100 µL MTB negative pooled

sputum (143,000 cells/µL), and the negative samples consisted of 100 µL negative pooled

sputum. For both high positive and negative samples, 100 µL of pooled sputum was aliquoted to

a 2 mL tube, the entire volume was sampled onto a swab and processed via the test workflow.

The high positive samples were run on five analyzers, immediately followed by negative

samples. This was repeated for a total of ten positive and ten negative samples.

Cartridge Stability

One year stability at ambient temperature (22 °C) and 45 °C was established in real-time. Five

replicates per time point of MTB positive (50 genome copies) and negative tests were

performed at 1 month, 2 months, 4 months, 6 months, 9 months and one year. Stability was

determined based on regression analysis of Cq values. Any percent change from time zero

(baseline) was calculated between the test time point performance and the baseline

performance $[(T_{test}-T_{baseline})/T_{baseline}]*100$ with 95% CI using the regression equation obtained for

plotting the mean values. If the assay performance shift from the baseline to the current time

point exceeds 10-15%, the cartridges were considered unusable.

Statistics

Cq values were plotted against log cell number/swab to obtain a standard curve. Slope

parameters and confidence intervals (CI) were estimated by linear regression of Cq values vs.

log copy number (https://www.graphpad.com/quickcalcs/linear2/). The value of the slope was

used to calculate PCR efficiency (25). Two-tailed Student's t-tests and clinical sensitivity and

specificity were calculated using Medcalc online package

(https://www.medcalc.org/calc/diagnostic_test.php). Pearson correlation tests were used to

generate R^2 values to evaluate correlations between the two lysis procedures. Differences

between the two tests were also examined graphically according to Bland & Altman (26). Plots

were generated with the difference in Cq of the bead beating lysis method on the y axis and the

Cq of heating lysis method on the x axis. The mean difference and the standard deviation of the

differences were calculated, and lines were drawn corresponding to the mean and the mean ± 2

standard deviations. A t-test with the null hypothesis of a mean difference equal to zero

(www.vassarstats.net/index.html) was performed. P values less than 0.05 were considered

statistically significant. Analysis of Variance ANOVA calculator

https://www.standarddeviationcalculator.io/anova-calculator was used to calculate the difference

between two or more means or components through significance tests.

RESULTS

Comparison of lysis methods

The RUO DASH MTB Test is an automated qPCR assay intended for the qualitative detection

of DNA from *Mycobacterium tuberculosis*. Since MTB is resistant to conventional bacterial lysis

techniques, we initiated our studies by comparing mechanical lysis and sonication for sample

processing prior to cartridge testing.

Paired oral swabs from 23 MTB-positive participants of varying bacterial loads were tested to

compare nuclease inactivation/bead beating vs. sonication (Supplemental methods; Figure S1).

Fourteen of the tongue swabs were positive in the sonication condition, and 11 were positive in

the heating/bead beating condition (Table S1). The Cqs were compared for the 11 samples that

were positive in both lysis conditions. Ten of the samples had lower Cqs (i.e., stronger signal) in

the sonication condition, and one had a lower Cq in the heating/bead beating. This sample was

considered an outlier by Bland Altman analysis (figure 2Sa). We hypothesize that there were

significantly different bacterial loads between the paired swabs for this sample as has been

reported in other studies (27, 28). When the apparent outlier was removed from the analysis,

the two lysis methods are highly correlated ($R^2 = 0.95$) (Figure 2Sb). The mean Cq difference

between the sonication lysis method and the heat and bead beating lysis method was 1.2 (95%

CI: 0.66, 1.71; (p=0.0006). Sonication was thereby deemed to be the more effective lysing

treatment and was used as the lysis step in all subsequent testing.

Analytical limit of Detection

The limit of detection (LOD) of the DASH MTB test was determined using negative tongue swab

samples spiked with MTB H37Ra (ATCC). Five of five swabs contrived with 10 cells/swab were

detected, and 20 of 20 contrived with 2.5 cells/swab were detected. Lower dilutions were not

tested because the sampling error at 1 cell/swab was too great, and the LOD was declared to

be 2.5 cells/swab.

Specificity

Cross-Reactivity: DNA from fourteen NTM strains and/or other bacterial strains that are

found in the mouth were tested to determine if they cross reacted in the DASH® MTB

test cartridge (Table 1). No positive results were observed in the MTB channel. The

procedural control average Cq for the tongue swab control was 29.6±0.3 and the average Cq

for the potentially cross-reactive species was 29.7±0.6 demonstrating that there is no real

difference between the means (P=0.7779). Thus, a valid, negative result was obtained for all

replicates indicating a lack of cross-reactivity at the concentration tested.

Microbial Interference: The same 14 bacterial strains used for cross-reactivity assessment

were used to contrive MTB positive samples with 60 MTB cells/swab, in triplicate. A valid,

positive result was obtained for all replicates tested, indicating a lack of assay interference

(Table 1). The average Cq of the positive controls without addition of any potentially interfering

strain was 31.4± 0.7, and the average Cq of the samples spiked with potentially interfering

strains was 30.9±0.9, demonstrating that there is no real difference between the means

(P=0.35) and indicating that the assay performance was similar with and without the presence

of the potentially interfering strains.

Swab Specimen Testing

A pilot study of 30 swab specimens (10 positive, 20 negative) was performed using the DASH

assay with no invalid results. The DASH assay had 70% sensitivity and 95% specificity

compared to sputum culture. The Xpert Ultra test applied to tongue swabs from the same

participants yielded a 67% sensitivity and 90% specificity (Table 2). The pilot study results

indicate that tongue swab specimens are compatible with the DASH MTB assay when

combined with the sonication lysis step.

A second larger study of 110 blinded swab specimens (70 positive, 40 negative) (Table S2 and

S3) was performed using the DASH assay with no invalid results. The DASH assay was 93%

sensitive and 100% specific when compared to the microbiological reference standard (MRS)

(Table 3). When compared to the Xpert Ultra sputum test results, the DASH assay accurately

detected the High and Medium semiquantitative (97% and 100%) samples and more

moderately detected the Low and Very Low (81% and 80%) samples. The DASH and the Xpert

Ultra tongue swab results had nearly equivalent sensitivity (93% vs. 90%) and equivalent

specificity (100%).

Sputum testing

Sampling sputum with a swab was first reported by Steadman, et al. in a multi-country

diagnostic accuracy evaluation of late prototype versions of two nPOC MTB tests (12). Sputum

usually has a higher bacillary load than non-sputum specimens in pulmonary TB (4). Therefore,

we performed a series of studies to determine if sputum can be adequately processed in the

DASH platform using the tongue swab workflow described above.

Characterization of Sputum as a Specimen

The challenges of isolating amplification-ready nucleic acid from sputum include the high

viscosity and heterogeneity of the sputum matrix, high concentrations of amplification inhibitors,

uneven distribution of the bacilli, relatively small amounts of MTB nucleic acid compared to

human nucleic acid, and the bacilli's resistance to lysis due to its thick cell wall with waxy coat

(19). A benefit of the sonication pretreatment is that the sample is lysed and thoroughly

homogenized before being transferred to the DASH cartridge for nucleic acid extraction,

amplification, and detection.

To determine the volume of sputum sampled by the Copan swab, we prepared a pooled sputum

specimen, dipped a swab into the specimen 5 times and weighed the swab head to determine

the average volume collected to be 95.0±19.3 µL (range 80 to 127 µL). We then tested 15

individual sputum specimens and observed that the average volume collected was 136.2±62.5

µL (range 65 to 260 µL) which was slightly more than with the pooled sputum. Moreover, the

quantity collected was more variable. To test if the large range of sputum volume would be

processed efficiently by the DASH platform, we added zero (N=3), 50 (N=5), and 300 (N=5) µL

of pooled sputum to the reactions spiked with MTB. The mean MTB Cqs of the 3 sputum

volumes were 30.5±0.3, 30.5±0.4, and 30.5±0.9, respectively. There was no significant

difference between the means (p=0.98809) indicating that the amount of sputum sampled by

the swab will not interfere with the sample processing in the DASH cartridge.

Assay Efficiency in the Presence of Sputum

To determine if using sputum as the specimen interferes with the PCR efficiency of the MTB

assay, the test linearity was determined by examining the relationship between Cq and MTB

concentration. The DASH MTB assay was linear (R^2= 0.99) from 20 to 2 million cell spiked

sputum specimens (Figure 3). The assay correctly identified MTB in all spiked samples. The

PCR efficiency of 97.4% was calculated from the line's slope of -3.39 [95%CI slope: -3.57,-3.21;

p < 0.001]. A highly efficient qPCR assay is required for optimal product yield, and thus low

LOD, and indicates that the sputum did not inhibit the assay (29).

Sputum Clinical Testing

One hundred sputum specimens (Table S4 and S5) were tested by the DASH assay with no

invalid results. Overall sensitivity was 96% and specificity was 88% relative to culture results

(Figure 4). The Xpert Ultra sensitivity and specificity for these specimens were identical to

DASH. DASH had 100% agreement with the Xpert Ultra semiquantitative categories of High,

Medium, Low, and Very Low and 57% agreement with Trace samples. Overall, nine samples

had false-positive results in either the DASH or Xpert Ultra test: three were positive in both

assays, and three were positive in one assay or the other (Figure 3B). Of these 9, 5 had prior

TB disease episodes, and the 6 Xpert Ultra-positive samples had Trace semiquantitative

results.

Near Point-of-Care Compatibility

To be compatible with LMIC peripheral healthcare settings, the DASH MTB test must function

with low-quality or intermittent power via external battery operation. It also needs to use tightly

sealed cartridges that retain amplicons generated during the testing (thus eliminating the need

for separate pre- and post-amplification rooms required for laboratory-based nucleic acid

amplification tests), and to have long term cartridge stability in settings that lack refrigeration

and air conditioning.

Lack of Cross-Contamination

A study was conducted to demonstrate that cross-contamination does not occur when

processing specimens with the sonication step followed by the single-use, self-contained

DASH® MTB test cartridges. High positive samples were run in five DASH® analyzers.

Negative samples were processed in the same DASH analyzer immediately following the

positive specimen. This testing scheme was performed twice for a total of twenty runs in five

analyzers, resulting in 10 positive and 10 negative correctly reported specimens with no cross

contamination observed.

Cartridge stability

The effect of long-term storage at ambient (22 °C) and elevated (45 °C) temperatures for over

one year was determined. No difference in performance after 373 days of incubation compared

to day zero was observed with cartridges incubated at either ambient or 45 °C (Figure S3).

Battery operation

An Anker Portable Power Station (PowerHouse 256Wh; Model A1720) was used to operate a

DASH analyzer using a custom 12V car charger adapter to a 4-pin DIN connector for 33 back-

to-back 15-minute tests totaling approximately 8.25 hours of operating time without any error.

Discussion

There is an urgent need for TB tests to be located at peripheral healthcare centers for rapid and

accurate MTB detection enabling providers to initiate therapy in the same clinical encounter

(30). In this study, we demonstrated the high analytical and clinical sensitivity and specificity of

the DASH MTB assay combined with a pre-cartridge sonication step using either tongue swabs

or sputum specimens.

Tongue swabs are recognized as a promising alternative diagnostic specimen to sputum with

high specificity but generally lower sensitivity, with an observed correlation between sputum

bacterial loads as measured by Xpert Ultra semiquantitative results and tongue swab positivity

(13). Since 2015, well over 21 studies have explored the use of tongue swabs as specimens

(31). From these studies, 4 key assay steps have been identified to improve test sensitivity:

nuclease inactivation; optimal bacterial lysis; maximizing the specimen volume tested either via

multiple PCR runs, high-volume PCR runs or solid phase extraction/concentration; and

multicopy target amplification (10, 27) . The DASH test was designed with these key steps in

mind. The combination of the DASH lysis buffer and sonication inactivates nucleases present in

oral specimens and lyses the notoriously durable MTB cells. The specimen is then transferred

to the DASH cartridge where the quantity of MTB target analyzed is maximized via sequence-

specific capture. The multicopy targets IS*6110* and IS*1081* are amplified and detected yielding

the high sensitivity (93%) and specificity (100%) observed in the study of 110 banked tongue

swab specimens.

Sputum specimens, when available, are the preferred MTB specimen, as they are predicted to

have the lowest false negative rate due to higher bacillary loads (32). The challenges of

isolating amplification-ready nucleic acid from sputum such as high sample viscosity and high

concentrations of PCR inhibitors are addressed in the DASH assay by the pre-cartridge

sonication step and the sequence specific DNA extraction method used in the DASH cartridge

(10, 19). In this study, we determined the range of sputum volume sampled when the Copan

swab was swirled in sputum and demonstrated that this volume did not affect MTB detection or

reduce PCR efficiency (Figure 3).

The DASH MTB test and the Xpert Ultra test had identical sensitivity (96%) and specificity

(88%) with this sample set of 100 sputum specimens (Figure 4A). Nine samples were false

positive for one or both assays (Figure 4B) which may imply that these specimens were near

the LOD of both assays. The semiquantitative values for the six false positive specimens in the

Xpert Ultra test were Trace positive. A proportion of Trace positives have been attributed to

residual MTB DNA from previous TB disease (33-36), and five of the nine false positive

specimens from this study were collected from participants reported to have had previous TB

disease. Recently, in high burden TB settings, it has been reported that up to one half of

patients with sputum Trace results were diagnosed with TB disease within 12 months (37-39)

which indicates that a Trace result may reflect paucibacillary disease when interpreted within

the appropriate clinical and imaging framework rather than an indeterminate result.

WHO has recently published updated target product profiles (TPP) for tuberculosis screening

tests (40) with three types of tests defined on the basis of healthcare setting, the complexity of

the test, the infrastructure, and the equipment and skills required: 1. Point-of-care tests defined

as instrument-free and not requiring any laboratory infrastructure (example: lateral flow test); 2.

Near point-of-care tests defined as preferably battery operated instruments that do not require

laboratory infrastructure (example: portable nucleic acid amplification test platform); and 3. Low

complexity tests requiring an instrument and basic laboratory infrastructure with basic technical

skills to use it (example: GeneXpert 10 color platform) (30). We have demonstrated that DASH

is compatible with nPOC settings in that DASH MTB cartridges are stable at elevated

temperatures, the DASH analyzer can be powered by an external battery, and the lack of cross

contamination eliminates the need for separate pre- and post-amplification rooms. In our

performance testing, we demonstrated that the DASH MTB assay met or exceeded the WHO

TPP minimal sensitivity requirements for both sputum (85%, 90%) and non-sputum i.e., tongue

swab specimens (75%, 80%), for both nPOC and low complexity settings, respectively. The

specificity of the sputum testing was less than the >95% optimal, but the non-sputum specificity

of 100% exceeded the optimal value.

There are limitations to this study. The procedural control is a synthetic DNA molecule which

does not report on the efficiency of cell lysis. In our next assay design iteration, the synthetic

construct will be replaced by a genetic target from *Bacillus atrophaeus* spores which will confirm

that efficient lysis has occurred. Additionally, the pre-DASH cartridge sonication step uses a

prototype sonicator that is not ready for transfer to untrained operators. The next generation

sonicator will be portable and battery operated and will not require training to set the applied

pressure to the tubes during sonication. The swab and sputum specimens had all been

previously frozen, and the freeze/thaw may have overestimated or underestimated the lysis

efficiency which could have skewed the test sensitivity. Moreover, the clinical sputum and

tongue swab specimens were tested by well-trained laboratorians. Future evaluations in nPOC

settings with nonlaboratory users processing fresh tongue swab and/or sputum specimens are

justified to demonstrate that laboratory training is not required and that the test performance is

comparable to that with frozen samples. Finally, the specimens tested were selected randomly

from storage not from consecutively collected specimens, which may have inadvertently

introduced sampling bias.

Despite these limitations, the initial characterization of the DASH MTB test demonstrated high

clinical and analytical sensitivity and specificity, robustness against cross-contamination, and

compatibility with settings that lack air conditioning and consistent power. Sensitive detection of

MTB from tongue swabs and sputum plus the rapid time to result indicate high potential for use

with same day diagnosis and treatment of active tuberculosis infection. A further advantage of

the DASH platform is that in addition to detecting MTB, it can be used for multi-disease

detection from a range of sample types such as nasal swabs for a multiplexed SARS-CoV-2,

Influenza A, and Influenza B test (17) to whole blood or plasma for an active hepatitis C

diagnostic test (16) thus optimizing resources and expanding access to testing outside siloed

testing programs (2).

Acknowledgement

The authors thank past and present members of the Center for Innovation in Global Health

Technologies, the Clinical Mycobacteriology & Epidemiology (CLIME) research group, and

study participants. We thank Zelalem Temesgen, MD for the gift of residual deidentified TB-

negative sputum specimens and the Rapid Research for Diagnostics Development in TB

Network (R2D2) funded by the National Institute of Allergy and Infectious Diseases of the

National Institutes of Health (award U01AI152087) for providing us with paired tongue swab

specimens for the lysis study. We thank Nuclein LLC for providing molded cartridge bodies that

were used to assemble DASH® MTB cartridges at Northwestern University.

Funding

This study was supported by the National Institute of Biomedical Engineering NIH U54

EB027049 (SMM, GAC, GT), the NIH-funded Third Coast Center for AIDS Research P30

AI117943 (SMM, GT), the National Institute of Allergy and Infected Disease NIH R01AI139254

(GAC), and Gates Foundation grant INV-004527 (GAC). The study sponsors played no role in

the design of any of the studies, in the collection, analysis and interpretation of data; in the

writing of the manuscript; nor in the decision to submit the manuscript for publication.

Declaration of competing interest

Dr. McFall received research support from Nuclein, LLC, the manufacturer of the DASH®PCR

System for other studies. Dr. McFall owns shares of Nuclein, LLC. Dr. Cangelosi was a paid

consultant for a different company, Formulatrix Inc., during part of the study period.

Table 1. Summary of performance of organisms tested on the RUO DASH®MTB Test for cross-

reactivity and microbial interference.

Organism	Source	Stock conc. (c/µL)	Conc. tested (c/rxn)	Cross-reactivity MTB negative	Microbial interference MTB positive
control (no potential interferent)	n/a	n/a	n/a	3/3	3/3
Mycobacterium abscessus	ATCC 19977D-5	3.74E+07	1.0E+06	3/3	3/3
Mycobacterium avium K-10	ATCC BAA968D-5	3.08E+07	1.0E+06	3/3	3/3
Mycobacterium genevense	ATCC 51233	2.08E+06	1.0E+06	3/3	3/3
Mycobacterium gordonae	ATCC 35760D-5	2.21E+07	1.0E+06	3/3	3/3
Mycobacterium intracellulare	ATCC 13209	6.74E+06	1.0E+06	3/3	3/3
Mycobacterium kansasii	ATCC 12478	1.23E+07	1.0E+06	3/3	3/3
Mycobacterium malmoense	ATCC 29571	2.51E+06	1.0E+06	3/3	3/3
Mycobacterium marinum	ATCC BAA535D-5	1.74E+07	1.0E+06	3/3	3/3
Mycobacterium smegmatis	ATCC 23037D-5	3.59E+07	1.0E+06	3/3	3/3
Mycobacterium terrae	ATCC 15755	2.72E+06	1.0E+06	3/3	3/3
Bordetella pertussis	ATCC 9797D-5	3.89E+07	1.0E+06	3/3	3/3
Psuedomonas aeruginosa	ATCC 47085D-5	2.05E+07	1.0E+06	3/3	3/3
Streptococcus pyogenes	ATCC 19615D-5	3.50E+07	1.0E+06	3/3	3/3
Streptococcus salivarius	BEI Resources, NIAID, NIH as part of the Human Microbiome Project: *Streptococ*	1.55E+06	1.0E+06	3/3	3/3

	cus salivarius, Strain SK126, HM-121		

524   Table 2. Tongue swab specimen pilot study.

	Sputum		Tongue Swab	
TB Status	Culture	Ultra	Ultra	DASH
Positive	10/10 (100%)	10/10 (100%)	6/9 (67%)	7/10 (70%)
Negative	20/20 (100%)	20/20 (100%)	9/10 (90%)	19/20 (95%)

526   Table 3. One-hundred and ten tongue swabs were tested in DASH MTB assay with results

527   compared to Ultra MTB test.

Ultra Sputum Ultra SQ (N)	DASH Tongue Swabs		Ultra Tongue Swabs	
	N	Sens. [95% CI]	N	Sens.[95% CI]
All Positives (70)	65/70	93% [84,98]	61/69*	88% [78,95]
High (35)	34/35	97% [85,100]	35/35	100% [90.100]
Medium (13)	13/13	100% [75,100]	13/13	100% [75,100]
Low (16)	13/16	81% [54,96]	11/16	69%[41,89]
Very Low (5)	4/5	80% [28,100]	3/4*	75% [19,99]
Trace (1)	0/1	0% [0,98]	0/1	0% [0,98]
	N	Spec. [95% CI]	N	Spec. [95% CI]
Negatives (40)	40/40	100% [91,100]	40/40	100% [91,100]
Error or Invalid	0	-	1	-

*One Ultra Xpert tongue swab gave an error on one of the Very Low samples, so there were 69

samples.

References

1.   World Health Organization. Global tuberculosis report 2025. Factsheet, Chrome

extension://efaidnbmnnnibpcajpcglclefindmkaj/https://cdn.who.int/media/docs/default-

source/global-tuberculosis-report-2025/global-tb-report-

2025_factsheet.pdf?sfvrsn=cd5722e6_5&download=true. Accessed 02/18/2026.

2.   Pai M, Dewan PK, Swaminathan S. 2023. Transforming tuberculosis diagnosis. Nature

Microbiology 8:756-759.

3.   Yerlikaya S, Holtgrewe LM-L, Broger T, Isaacs C, Nahid P, Cattamanchi A, Denkinger C,

M. . 2023. Innovative COVID-19 point-of-care diagnostics suitable for tuberculosis

diagnosis: a scoping review protocol. BMJ Open 13:e065194.

4.   Theron G, Peter J, Calligaro G, Meldau R, Hanrahan C, Khalfey H, Matinyenya B,

Muchinga T, Smith L, Pandie S, Lenders L, Patel V, Mayosi BM, Dheda K. 2014.

Determinants of PCR performance (Xpert MTB/RIF), including bacterial load and

inhibition, for TB diagnosis using specimens from different body compartments. Sci Rep

4:5658.

5.   Peter JG, Theron G, Muchinga TE, Govender U, Dheda K. 2012. The diagnostic

accuracy of urine-based Xpert MTB/RIF in HIV-infected hospitalized patients who are

smear-negative or sputum scarce. PLoS One 7:e39966.

6.   Bezuidenhout C, Long L, Nichols B, Meyer-Rath G, Fox MP, Olifant S, Theron G,

Fiphaza K, Pieruccini M, Ruhwald M, Penn-Nicholson A, Fourie B, Medina-Marino A.

2025. Using sputum and tongue swab specimens for in-home point-of-care targeted

universal testing for tuberculosis of household contacts: an acceptability and feasibility

analysis. BMJ Global Health 10:e018131.

7.   David A, Singh L, Peloakgosi-Shikwambani K, Nsingwane Z, Molepo V, Cangelosi G, da

Silva P, Stevens W, Scott L. 2025. Diagnostic accuracy of self-collected tongue swabs

for Mycobacterium tuberculosis complex detection in individuals being assessed for TB

in South Africa using the Xpert MTB/RIF Ultra assay. Clin Microbiol Infect

doi:10.1016/j.cmi.2025.01.029.

8.   Luabeya AK, Wood RC, Shenje J, Filander E, Ontong C, Mabwe S, Africa H, Nguyen

FK, Olson A, Weigel KM, Jones-Engel L, Hatherill M, Cangelosi GA. 2019. Noninvasive

Detection of Tuberculosis by Oral Swab Analysis. J Clin Microbiol 57.

9.   Mbuli C, Jean Bosco TF, Nsamenang R, Nestor B, Nguimfack G, Mbuh NN, Konso J,

Mana ZA, Arthur N, Magdalene TN, Denis N, Ndi NN, Goupeyou Wandji IA, Fundoh M,

Toussaint MG, Bello O, Paul M, Adeline F, Comfort V, Teyim P, Donkeng Donfack VF,

Garg T, Creswell J, Sander M, the RTBC. 2025. Diagnostic performance of the Pluslife

MiniDock MTB and Molbio MTB Ultima assays to detect tuberculosis from tongue and

sputum swabs among outpatients and in active case finding in Cameroon. medRxiv

doi:10.1101/2025.09.11.25335435:2025.09.11.25335435.

10.   Olson AM, Wood RC, Weigel KM, Yan AJ, Lochner KA, Dragovich RB, Luabeya AK,

Yager P, Hatherill M, Cangelosi GA. 2025. High-sensitivity detection of Mycobacterium

tuberculosis DNA in tongue swab samples. J Clin Microbiol 63:e0114024.

11.   Rockman L, Abdulgader SM, Minnies S, Palmer Z, Naidoo CC, Venter R, Naidoo D,

Ndlangalavu G, Reeve BWP, Medina-Marino A, Bull TJ, Olson AM, Wood R, Cangelosi

GA, Warren RM, Theron G. 2025. Oral washes and tongue swabs for Xpert MTB/RIF

Ultra-based tuberculosis diagnosis in people with and without the ability to make sputum.

Clin Infect Dis doi:10.1093/cid/ciaf397.

12.   Steadman A, Kumar KM, Asege L, Kato-Maeda M, Mukwatamundu J, Shah K, Trang T,

Ball A, Khimani K, Kim Dung DT, Michael JS, Christopher DJ, Phan H, Yerlikaya S,

Nahid P, Denkinger CM, Cattamanchi A, Andama A. 2025. Diagnostic accuracy of swab-

based molecular tests for tuberculosis using near-point-of-care platforms: a multi-country

evaluation. EBioMedicine 121:105991.

13.   Wood RC, Luabeya AK, Dragovich RB, Olson AM, Lochner KA, Weigel KM, Codsi R,

Mulenga H, de Vos M, Kohli M, Penn-Nicholson A, Hatherill M, Cangelosi GA. 2024.

Diagnostic accuracy of tongue swab testing on two automated tuberculosis diagnostic

platforms, Cepheid Xpert MTB/RIF Ultra and Molbio Truenat MTB Ultima. J Clin

Microbiol 62:e0001924.

14.   Moe CA, Luswata R, Barrameda J, Le H, Muzazu S, Crowder R, Andama AO,

Denkinger C, Muyoyeta M, Phan H, Cattamanchi A, Yu C, Network TSS. 2025.

Diagnostic yield of tongue swab- compared to sputum-based molecular testing for

tuberculosis in four high-burden countries. medRxiv

doi:10.1101/2025.07.03.25330836:2025.07.03.25330836.

15.   Butzler MA, Reed JL, Knapton KM, Afzal T, Agarwal AK, Schaeffer J, Saraiya N, Oti L,

White ER, Giacobbe E, Simons LM, Ozer EA, McFall SM. 2023. Evaluation of the

analytical performance of the 15-minute point-of-care DASH™ SARS-CoV-2 RT-qPCR

test. Diagn Microbiol Infect Dis 108:116120.

16.   Reed JL, Butzler MA, Hawkins CA, Manabe YC, Holden J, Thomas DL, Cox AL, McFall

SM. 2025. Development of a Rapid Automated Point-of-Care Test for Hepatitis C Viral

RNA on the DASH® Rapid PCR System. J Infect Dis doi:10.1093/infdis/jiaf608.

17.   Zhu H, Baumeister M, Klug H, Arms T, Cadenhead S, Earp M, Shelton J, Karberg M,

McFall S, Hully J. 2025. A-416 Clinical and Analytical Evaluation of the 15-minute, FDA-

Cleared, CLIA-Waived, DASH® SARS-CoV-2 and Flu A/B Test Performed on the Point-

of-Care DASH® Rapid PCR System. Clinical Chemistry 71:hvaf086.400.

18.   Reed JL, Basu D, Butzler MA, McFall SM. 2017. XtracTB Assay, a Mycobacterium

603   tuberculosis molecular screening test with sensitivity approaching culture. Scientific

604   reports 7:1-12.

605   19.   Reed JL, Walker ZJ, Basu D, Allen V, Nicol MP, Kelso DM, McFall SM. 2016. Highly

606   sensitive sequence specific qPCR detection of Mycobacterium tuberculosis complex in

607   respiratory specimens. Tuberculosis (Edinb) 101:114-124.

608   20.   Yan AJ, Olson AM, Weigel KM, Luabeya AK, Heiniger E, Hatherill M, Cangelosi GA,

609   Yager P. 2024. Detection of Mycobacterium tuberculosis from tongue swabs using

610   sonication and sequence-specific hybridization capture. PLoS One 19:e0308235.

611   21.   Abdulgader SM, Chiwaya AM, Nwamba WV, Reeve BWP, Palmer Z, Mishra H, Mbu D,

612   Lushozi N, Nkwanyana Z, Ruhwald M, Penn-Nicholson A, Warren R, Theron G. 2025.

613   Diagnostic accuracy of Truenat MTB Ultima on sputum for pulmonary tuberculosis

614   diagnosis in an HIV-endemic setting. Clin Microbiol Infect 31:1203-1209.

615   22.   Mishra H, Reeve BWP, Palmer Z, Caldwell J, Dolby T, Naidoo CC, Jackson JG,

616   Schumacher SG, Denkinger CM, Diacon AH, van Helden PD, Marx FM, Warren RM,

617   Theron G. 2020. Xpert MTB/RIF Ultra and Xpert MTB/RIF for diagnosis of tuberculosis in

618   an HIV-endemic setting with a high burden of previous tuberculosis: a two-cohort

619   diagnostic accuracy study. The Lancet Respiratory Medicine 8:368-382.

620   23.   Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, Mueller R, Nolan T,

621   Pfaffl MW, Shipley GL, Vandesompele J, Wittwer CT. 2011. Primer sequence disclosure:

622   a clarification of the MIQE guidelines. Clin Chem 57:919-21.

623   24.   McNerney MP, Zhang Y, Steppe P, Silverman AD, Jewett MC, Styczynski MP. 2019.

624   Point-of-care biomarker quantification enabled by sample-specific calibration. Sci Adv

625   5:eaax4473.

626   25.   Lutfalla G, Uze G. 2006. Performing quantitative reverse-transcribed polymerase chain

627   reaction experiments. Methods Enzymol 410:386-400.

628   26.   Bland JM, Altman DG. 1986. Statistical methods for assessing agreement between two

629   methods of clinical measurement. Lancet 1:307-10.

630   27.   Steadman A, Andama A, Ball A, Mukwatamundu J, Khimani K, Mochizuki T, Asege L,

631   Bukirwa A, Kato JB, Katumba D, Kisakye E, Mangeni W, Mwebe S, Nakaye M, Nassuna

632   I, Nyawere J, Nakaweesa A, Cook C, Phillips P, Nalugwa T, Bachman CM, Semitala FC,

633   Weigl BH, Connelly J, Worodria W, Cattamanchi A. 2024. New manual qPCR assay

634   validated on tongue swabs collected and processed in Uganda shows sensitivity that

635   rivals sputum-based molecular TB diagnostics. Clin Infect Dis doi:10.1093/cid/ciae041.

636   28.   Wood Rachel C, Goodgion S, Olson Alaina M, Luabeya Angelique K, Hatherill M,

637   Cangelosi Gerard A. 2025. Testing tongue swab samples by Cepheid Xpert MTB/RIF

638   Ultra: comparison of two protocols applied to samples from persons with low-bacillary

639   load TB. Microbiology Spectrum 13:e01493-25.

640   29.   Arezi B, Xing W, Sorge JA, Hogrefe HH. 2003. Amplification efficiency of thermostable

641   DNA polymerases. Anal Biochem 321:226-35.

642   30.   Kohli M, Korobitsyn A, Ismail N, Zignol M, Kasaeva T, Dewan P, Ruhwald M. 2025.

643   WHO target product profile for TB detection at peripheral settings: 2024 update. PLOS

644   Glob Public Health 5:e0004612.

645   31.   Church EC, Steingart KR, Cangelosi GA, Ruhwald M, Kohli M, Shapiro AE. 2024. Oral

646   swabs with a rapid molecular diagnostic test for pulmonary tuberculosis in adults and

647   children: a systematic review. The Lancet Global Health 12:e45-e54.

648   32.   Kendall E. 2025. Novel near-point-of-care tuberculosis molecular tests: Navigating the

649   repercussions of sensitivity tradeoffs [version 1]. VeriXiv 2.

650   33.   Costantini L, Marando M, Gianella P. 2020. Long-Term GeneXpert Positivity after

651   Treatment for Pulmonary Tuberculosis. Eur J Case Rep Intern Med 7:001737.

652   34.   Dorman SE, Schumacher SG, Alland D, Nabeta P, Armstrong DT, King B, Hall SL,

653   Chakravorty S, Cirillo DM, Tukvadze N, Bablishvili N, Stevens W, Scott L, Rodrigues C,

654   Kazi MI, Joloba M, Nakiyingi L, Nicol MP, Ghebrekristos Y, Anyango I, Murithi W, Dietze

655   R, Lyrio Peres R, Skrahina A, Auchynka V, Chopra KK, Hanif M, Liu X, Yuan X, Boehme

656   CC, Ellner JJ, Denkinger CM. 2018. Xpert MTB/RIF Ultra for detection of Mycobacterium

657   tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy

658   study. Lancet Infect Dis 18:76-84.

659   35.   Theron G, Venter R, Calligaro G, Smith L, Limberis J, Meldau R, Chanda D, Esmail A,

660   Peter J, Dheda K. 2016. Xpert MTB/RIF Results in Patients With Previous Tuberculosis:

661   Can We Distinguish True From False Positive Results? Clin Infect Dis 62:995-1001.

662   36.   Theron G, Venter R, Smith L, Esmail A, Randall P, Sood V, Oelfese S, Calligaro G,

663   Warren R, Dheda K. 2018. False-Positive Xpert MTB/RIF Results in Retested Patients

664   with Previous Tuberculosis: Frequency, Profile, and Prospective Clinical Outcomes. J

665   Clin Microbiol 56.

666   37.   Dalmat RR, Visek C, Budiawan E, Stein G, Nalutaaya A, Mukiibi J, Nantale M, Biché P,

667   Sung J, Magcaba Z, Ngcobo N, Morton JF, Lenn M, Aucock S, Shapiro AE, Steadman

668   A, Draper R, Ganguloo A, Wilson D, Katamba A, Kendall EA, Drain PK. 2025.

669   Cumulative TB disease burden following sputum Xpert Ultra 'Trace' results in clinical

670   settings: Results from a multi-site observational clinical study. medRxiv

671   doi:10.1101/2025.07.14.25331384.

672   38.   Sava C, Iuhas A, Marinău C, Gali□ R, Rus M, Sava M. 2025. Clinical Relevance of

673   Trace-Positive Results in Xpert MTB/RIF Ultra for Tuberculosis Diagnosis in a High-

674   Burden Setting: A Retrospective Cohort Study. Diagnostics (Basel) 15.

675   39.   Sung J, Nantale M, Nalutaaya A, Biché P, Mukiibi J, Kamoga CE, Akampurira J,

676   Kayondo F, Kiyonga R, Mukiibi M, Nakasolya O, McGeehan M, Dowdy DW, Katamba A,

677   Kendall EA. 2024. Evidence for Tuberculosis in Individuals With Xpert Ultra "Trace"

678   Sputum During Screening of High-Burden Communities. Clin Infect Dis 78:723-729.

679   40.   World Health Organization. Target product profiles for tuberculosis screening tests.

680   2025. https://www.who.int/publications/i/item/9789240113572. Accessed October 17,

681   2025.

Figure Legends

Figure 1A) DASH® Rapid PCR System analyzer. B) RUO DASH®MTB cartridge contains all

reagents required to run a test including sample prep and qPCR amplification and detection.

The top image shows the front of the cartridge with stabilized reagents outlined in white boxes.

The bottom image shows the back of the cartridge with the chambers labeled with the test

functions. C1-C6 = Chambers 1-6; LTC = liquid transfer capsule. C) MTB assay workflow. Total

time ≈ 20 minutes. 1) Specimens are collected from tongues or expectorated sputum using a

flocked swab; 2) The swab containing the sample is placed in the lysis tube containing 600 µL

lysis buffer and 150-200 mg 0.1 mm diameter glass beads; 3) The sample is sonicated for 3

minutes at power/amplitude of "4" with a downward force of 25-30N;4) 450 µL specimen is

transferred to the sample chamber of the DASH MTB cartridge with a disposable pipet; 5) The

cartridge is inserted into the DASH analyzer, and the MTB test is run automatically. After 14.5

minutes, an easy-to-read positive/negative result appears on the unit's touch screen.

Figure 2. Study profiles for tongue swab and sputum specimen testing. STARDT (Standards for

Reporting of Diagnostic Accuracy Studies) figures for tongue swab and sputum specimens. A)

The STARD algorithm was conducted for inclusion of participants for the tongue swab specimen

study. * Participants with confirmed negative TB were omitted randomly to test half of available

n = 36; ** Participants with confirmed positive TB but no swabs were available for testing and/or

used in previous studies n = 24;*** Participants with confirmed positive TB but no available

Xpert Semiquantitative data available n = 50.

B) The STARD algorithm was conducted for inclusion of participants for the sputum specimen

study. 100 sputum specimens were randomly selected for DASH testing from prospectively

recruited participants with valid culture and Ultra results.

708 Figure 3. Linear and Efficient MTB amplification in the presence of sputum indicates a lack of

709 PCR inhibition caused by sputum. Standard curve of log copies *Mycobacterium tuberculosis* (x)

710 versus Cq (y). Equation of line: y = -3.39X + 34.74 [95%CI slope -3.57,-3.21]; R2 = 0.99. PCR

711 efficiency calculated from the slope 97.4%.

713 Figure 4. A) Forest plot of Xpert Ultra (orange circles) and DASH (blue diamonds) sensitivity

714 and specificity on sputum specimens with culture as the comparator. Both assays had identical

715 positive and negative agreement percentages to culture. B) Nine samples were false positive in

716 either the DASH and/or Xpert Ultra assays, and 5 of the participants reported previous TB

717 disease. A bar is present if the sample was positive with Xpert Ultra (orange), DASH (blue), or

718 the participant reported previous TB disease (black).

A

B

c

or

| Collect sample on swab | Transfer sample to lysis tube | Lyse by sonication 3 min. | Transfer lysed sample to cartridge | Run test 14.5 min. |

735   Figure 2

738   Figure 3

740   Figure 4

744